Immunoglobulin isotypes in multiple myeloma: Laboratory correlates and prognostic implications in total therapy protocols

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA, and Cancer Research and Biostatistics, Seattle, WA, USA. E-mail: .
British Journal of Haematology (Impact Factor: 4.71). 04/2009; 145(1):134-7. DOI: 10.1111/j.1365-2141.2008.07547.x
Source: PubMed

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Fanconi Anemia (FA)/BRCA DNA damage repair pathway plays a critical role in the cellular response to stress induced by DNA alkylating agents and greatly influences drug response in cancer treatment. We recently reported that FA/BRCA DNA damage repair pathway genes are overexpressed and causative for resistance in multiple myeloma (MM) cell lines selected for resistance to melphalan. We hypothesized that the FA/BRCA DNA damage repair pathway mediates response and resistance to chemotherapeutic agents used to treat multiple myeloma and other cancers, and targeting this pathway is vital to overcoming drug resistance. In this dissertation, we show that FA/BRCA pathway genes are collectively overexpressed in MM, prostate, and ovarian cancer cell lines selected for resistance to melphalan and cisplatin, respectively. Interestingly, cells selected for resistance to topoisomerase II inhibitors selectively overexpress only FANCF. We also show that FA/BRCA pathway expression can be inhibited by the proteasome inhibitor bortezomib. FA/BRCA pathway mRNA expression was inhibited by bortezomib in myeloma cell lines and patient samples. FANCD2 gene and protein expression are downregulated by bortezomib, and remain attenuated in the face of melphalan treatment. Melphalan-induced FANCD2 foci formation was also inhibited by bortezomib, and this drug enhanced melphalan-induced DNA damage, likely via inhibition of FA-mediated DNA damage repair. Next, we analyzed regulation of the FA/BRCA pathway. We demonstrate that NF-kappaB, specifically the Re1B/p50 subunits, transcriptionally regulates members of the FA/BRCA pathway, and inhibition of these subunits by siRNA, BMS-345541, and bortezomib reduces FA/BRCA pathway expression. Furthermore, knocking down Re1B and p50 simultaneously attenuates FANCD2 protein expression and results in diminished DNA repair and enhanced sensitivity to melphalan. Importantly, melphalan resistance was restored when FANCD2 was re-expressed in these cells. We also show that bortezomib regulates FANCD2 protein expression directly, by inhibiting FANCD2 synthesis. Finally, we demonstrate that low-dose bortezomib arrests cells in G0/G1 and also overcomes the S-phase arrest induced by melphalan, likely via inhibition of ATR. Overall, our findings provide evidence for targeting the FA/BRCA pathway, either directly or indirectly, via inhibition of NF-kappaB or ATR, to enhance chemotherapeutic response and reverse drug resistance in multiple myeloma and other cancers.
    Preview · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Virtual-ESPRIT (VESPA) imposes a slight constraint on the array i.e. only a pair of identical sensors are required. We follow the classical procedure to define the sensitivity of VESPA with respect to each model parameter, and derive closed forms for the sensitivity formulas. We justify our derivations by comparing the theoretical formulas with the results from Monte Carlo simulations. Additionally, we demonstrate, by simulations, that VESPA is more robust to model mismatches than ESPRIT in most situations
    No preview · Conference Paper · Dec 1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: Management strategies for multiple myeloma (MM) have continued to evolve as the result of innovative treatment modalities and efficacy data used in establishing new standards of care, including new combination therapy. Most commonly diagnosed in the growing elderly population, MM continues to be one of the most costly cancers because of the need for stem cell transplant and medication used in initial and relapse stages, as well as in supportive care. The National Comprehensive Cancer Network and the International Myeloma Workgroup maintain guidelines that outline diagnosis strategies, disease staging, and treatment algorithms according to disease severity of MM and transplant eligibility of the patient This review highlights these new treatment approaches to MM, including an overview of supportive care and emerging pipeline agents. With the recent advancements in MM, the need for more cost-effective strategies in managing this condition is heightened. {Formulary. 2008;44:204-213).
    No preview · Article · Jul 2009
Show more